This review summarizes the 2013-2014 literature on sugammadex to identify answered and unanswered questions regarding its clinical use.
Highlights gaps in sugammadex evidence; leaves open key questions for prospective trials.
Since its launch in 2008, sugammadex has been considered one of the most significant developments in anaesthesia-related pharmacology. With almost 500 sugammadex-related publications and over nine million patient exposures worldwide, user experience and scientific data have grown exponentially. However, several important questions are yet to be answered. This article reviews the sugammadex-related literature in 2013 and 2014 to determine which of these questions have been answered more fully over the last 18 months and which questions require more information and research.
No takes yet. Share an insight, caveat, or question.
Thomas Ledowski (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: